These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 19598262)

  • 61. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.
    Tsuchiya A; Sakamoto M; Yasuda J; Chuma M; Ohta T; Ohki M; Yasugi T; Taketani Y; Hirohashi S
    Am J Pathol; 2003 Dec; 163(6):2503-12. PubMed ID: 14633622
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer.
    Ricciardelli C; Ween MP; Lokman NA; Tan IA; Pyragius CE; Oehler MK
    BMC Cancer; 2013 Oct; 13():476. PubMed ID: 24124770
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers.
    Toyama A; Suzuki A; Shimada T; Aoki C; Aoki Y; Umino Y; Nakamura Y; Aoki D; Sato TA
    Cancer Sci; 2012 Apr; 103(4):747-55. PubMed ID: 22321069
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.
    Samimi G; Varki NM; Wilczynski S; Safaei R; Alberts DS; Howell SB
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5853-9. PubMed ID: 14676106
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
    Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
    J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice.
    Matsuo Y; Tashiro H; Yanai H; Moriya T; Katabuchi H
    Med Mol Morphol; 2015 Sep; 48(3):146-54. PubMed ID: 25398420
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Overexpression of Long Noncoding RNA E2F-Mediated Cell Proliferation Enhancing Long Noncoding RNA Is Involved in the Development of Chemoresistance of Cancer Cells to Carboplatin in Ovarian Endometrioid Adenocarcinoma.
    Zhao L; Yang J; Liu X; Fu X; Ding Y; Wang C
    Cancer Biother Radiopharm; 2019 Nov; 34(9):566-571. PubMed ID: 31621389
    [No Abstract]   [Full Text] [Related]  

  • 68. Fibroblast growth factor receptor 2 expression may be involved in transformation of ovarian endometrioma to clear cell carcinoma of the ovary.
    Taniguchi F; Itamochi H; Harada T; Terakawa N
    Int J Gynecol Cancer; 2013 Jun; 23(5):791-6. PubMed ID: 23640291
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
    He Y; Wu AC; Harrington BS; Davies CM; Wallace SJ; Adams MN; Palmer JS; Roche DK; Hollier BG; Westbrook TF; Hamidi H; Konecny GE; Winterhoff B; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Tinker AV; Gilks CB; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
    Oncogene; 2016 Jan; 35(4):468-78. PubMed ID: 25893298
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Metabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival.
    Amano Y; Mandai M; Yamaguchi K; Matsumura N; Kharma B; Baba T; Abiko K; Hamanishi J; Yoshioka Y; Konishi I
    Oncotarget; 2015 Sep; 6(28):26002-17. PubMed ID: 26318292
    [TBL] [Abstract][Full Text] [Related]  

  • 71. HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival.
    Li B; Jin H; Yu Y; Gu C; Zhou X; Zhao N; Feng Y
    Int J Gynecol Cancer; 2009 Nov; 19(8):1347-52. PubMed ID: 20009888
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Specific expression of hepatocyte nuclear factor-1beta in the ovarian clear cell adenocarcinoma and its application to cytological diagnosis.
    Higashiguchi A; Yamada T; Susumu N; Mori T; Suzuki A; Aoki D; Sakamoto M
    Cancer Sci; 2007 Mar; 98(3):387-91. PubMed ID: 17270029
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas.
    Nishimura S; Tsuda H; Ito K; Takano M; Terai Y; Jobo T; Kigawa J; Sugiyama T; Yaegashi N; Aoki D
    Int J Gynecol Cancer; 2010 Feb; 20(2):220-6. PubMed ID: 20134266
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues.
    Melhem A; Yamada SD; Fleming GF; Delgado B; Brickley DR; Wu W; Kocherginsky M; Conzen SD
    Clin Cancer Res; 2009 May; 15(9):3196-204. PubMed ID: 19383827
    [TBL] [Abstract][Full Text] [Related]  

  • 75. ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component.
    Nishikimi K; Kiyokawa T; Tate S; Iwamoto M; Shozu M
    Histopathology; 2015 Dec; 67(6):866-71. PubMed ID: 25913291
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma.
    Kitamura S; Yamaguchi K; Murakami R; Furutake Y; Higasa K; Abiko K; Hamanishi J; Baba T; Matsumura N; Mandai M
    Cancer Sci; 2021 Nov; 112(11):4627-4640. PubMed ID: 34464482
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublines.
    Chen M; Huang H; He H; Ying W; Liu X; Dai Z; Yin J; Mao N; Qian X; Pan L
    Cancer Sci; 2015 Aug; 106(8):1075-83. PubMed ID: 26033570
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Magnetic resonance imaging findings for discriminating clear cell carcinoma and endometrioid carcinoma of the ovary.
    Morioka S; Kawaguchi R; Yamada Y; Iwai K; Yoshimoto C; Kobayashi H
    J Ovarian Res; 2019 Feb; 12(1):20. PubMed ID: 30803452
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer.
    Liu J; Agopiantz M; Poupon J; Wu Z; Just PA; Borghese B; Ségal-Bendirdjian E; Gauchotte G; Gompel A; Forgez P
    Clin Cancer Res; 2017 Nov; 23(21):6516-6528. PubMed ID: 28790113
    [No Abstract]   [Full Text] [Related]  

  • 80. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses.
    Tsuda H; Ito YM; Ohashi Y; Wong KK; Hashiguchi Y; Welch WR; Berkowitz RS; Birrer MJ; Mok SC
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6880-8. PubMed ID: 16203778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.